Articlenpj antimicrobials and resistance2024
Regulation of erm(T) MLS
Article in npj antimicrobials and resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Delabelling suspected amoxicillin allergy in pediatric patients using oral challenge: a retrospective study from Northwestern Ontario.European journal of pediatrics · 2026Article
- The Complexity of erm-Mediated Resistance: Structural and Functional Perspectives From β-Hemolytic Streptococci.Molecular microbiology · 2026Review
- Machine learning-based discovery of GW3965 as a therapeutic compound against invasive emm92-type group A Streptococcus.npj antimicrobials and resistance · 2026Article
- Dominance of the ST20Microorganisms · 2026Article
- Machine learning-based discovery of GW3965 as a therapeutic compound against invasive emm92-type group A Streptococcus.Research square · 2026Article
- Molecular epidemiology and antimicrobial susceptibility of group A Streptococcus isolated from children in Greece during 2023.Infection · 2026Article
- Transcriptome of macrolide-resistantMicrobiology resource announcements · 2025Article
- Insights into MLSJAC-antimicrobial resistance · 2025Article
- Structural and genomic insights into erythromycin and clindamycin resistance of group BFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In the last decade, invasive group A Streptococcus (iGAS) infections have doubled in the US, with equivalent increases in MLS
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.